Conference Day Two | Wednesday, November 20 8:00 am Coffee & Networking 8:50 am Chair’s Opening Remarks Nina Horowitz Chief Scientific Officer, ImmuneBridge Enhancing Therapeutic Precision to Identify Critical Biomarkers, Establish Rigorous Specificity Standards, & Improve the Accuracy & Effectiveness Of Cell Therapy Interventions 9:30 am Fireside Chat: Mapping the Crucial Role of Donor Selection in the Future of Biotech & Pharma to Streamline Commercialization Ben Beneski Vice President - Product Development & Manufacturing, Allogene Therapeutics Armin Rath Chief Operating Officer, Cytovia Therapeutics Stephanie Dormesy Senior Director, Cell Sourcing Partnerships Clinical Services Administration, Comprehensive Cell Solutions Nina Horowitz Chief Scientific Officer, ImmuneBridge Synopsis To view full session details, download the agenda here 10:00 am Comparing Donor-Derived & iPSC-Derived Therapies for Market Entry & Long-Term Viability Armin Rath Chief Operating Officer, Cytovia Therapeutics Synopsis To view full session details, download the agenda here 10:30 am Morning Refreshments & Networking 11:30 am Enhancing Donor Selection in Autologous Cell Therapy: Overcoming Challenges in Process Optimization & Scaling Up with Consistency & Safety Nidheesh Dadheech Cell Therapy Lead, University of Alberta Synopsis To view full session details, download the agenda here Integrating Robust Donor Selection Methods into Manufacturing, Scale-Up Operations & Downstream Drug Development to Maximize Therapeutic Effects 12:00 pm Pre-Clinical Ex Vivo Efficacy for Cell & Gene Therapies – A Donor Case Study Raluca Dumitru Scientific Sales Director, Charles River Laboratories Synopsis To view full session details, download the agenda here Critical Considerations in Donor Selection: Balancing Safety, Risk-Benefit Profiles, & Selecting Optimal Starting Materials between Donor-Derived & iPSC Therapies 12:15 pm Audience Led Discussion: Balancing Safety & Benefit-Risk in Donor Selection by Evaluating Metabolic Fitness, Memory & Cytokine Risks Nina Horowitz Chief Scientific Officer, ImmuneBridge Synopsis To view full session details, download the agenda here 12:45 pm Lunch & Networking 1:45 pm Advancing Cryopreservation Strategies for Donor Products by Enhancing Viability, Ensuring Long-Term Stability, & Maximizing Therapeutic Efficacy Tracey Turner Principal Scientist -Formulation & Cryobiology, Bristol Myers Squibb Synopsis To view full session details, download the agenda here 2:15 pm Roundtable Discussion: Evaluating Starting Materials for Donor Cells with a Focus on Quality, Reliability, & Logistics Considerations Stephen Chen CTO, Tevogen Bio Synopsis To view full session details, download the agenda here 2:45 pm Chair’s Closing Remarks Jesse Cotari Co-Founder & Scientific Advisor, ImmuneBridge 3:00 pm Close of Summit DAY ONE REGISTER